Biodexa Pharmaceuticals PLC
BDRX5.480USD
+0.240+4.78%
Handelsschluss 11/14, 16:00（ET）Kurse um 15 Minuten verzögert
33.95BMarktkapitalisierung
--KGV TTM
mehr Informationen über Biodexa Pharmaceuticals PLC Unternehmen
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
Biodexa Pharmaceuticals PLC Informationen
BörsenkürzelBDRX
Name des UnternehmensBiodexa Pharmaceuticals PLC
IPO-datumDec 08, 2014
CEOMr. Stephen A. Stamp
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
GeschäftsjahresendeDec 08
Addresse1 Caspian Point
StadtABINGDON
BörseNASDAQ Capital Market Consolidated
LandUnited Kingdom
PostleitzahlCF10 4DQ
Telefon4401235888300
Websitehttps://www.biodexapharma.com/
BörsenkürzelBDRX
IPO-datumDec 08, 2014
CEOMr. Stephen A. Stamp
Führungskräfte von Biodexa Pharmaceuticals PLC
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
Belgium
381.00K
100.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Thu, Oct 2
Aktualisiert: Thu, Oct 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Cavalry Fund I Management, LLC
2.83%
Brio Capital Management LLC
2.71%
UBS Switzerland AG
1.12%
Abbe (Richard)
0.39%
Bukwang Pharmaceutical Co., Ltd.
0.23%
Andere
92.73%
Aktionäre
Aktionäre
Anteil
Cavalry Fund I Management, LLC
2.83%
Brio Capital Management LLC
2.71%
UBS Switzerland AG
1.12%
Abbe (Richard)
0.39%
Bukwang Pharmaceutical Co., Ltd.
0.23%
Andere
92.73%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
5.75%
Bank and Trust
1.12%
Corporation
0.56%
Individual Investor
0.39%
Investment Advisor
0.23%
Hedge Fund
0.07%
Research Firm
0.02%
Andere
91.86%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
27
38.43K
6.20%
+24.49K
2025Q2
36
46.40K
7.49%
+35.30K
2025Q1
38
272.70K
5.41%
+162.94K
2024Q4
37
258.63K
38.68%
+145.03K
2024Q3
39
166.61K
38.54%
+138.41K
2024Q2
36
78.92K
24.69%
+69.19K
2024Q1
28
31.04K
21.44%
+27.53K
2023Q4
30
32.82K
23.15%
+31.84K
2023Q3
21
574.00
6.29%
-2.15K
2023Q2
21
425.00
5.59%
-1.99K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Cavalry Fund I Management, LLC
17.52K
2.83%
+17.52K
--
May 20, 2025
Brio Capital Management LLC
16.77K
2.71%
+11.06K
+193.61%
Nov 14, 2024
UBS Switzerland AG
199.00
0.03%
-815.00
-80.37%
Jun 30, 2025
Abbe (Richard)
2.43K
0.39%
+2.43K
--
Jul 19, 2024
Bukwang Pharmaceutical Co., Ltd.
1.42K
0.23%
+1.42K
--
Apr 01, 2024
Melior Pharmaceuticals I, Inc.
1.42K
0.23%
+1.42K
--
Apr 01, 2024
Mercer Street Capital Partners, LLC
1.42K
0.23%
+793.00
+126.88%
Apr 01, 2024
GAMMA Investing LLC
1.35K
0.22%
+158.00
+13.23%
Sep 30, 2025
GS Capital Partners LLC
631.00
0.1%
+631.00
--
Apr 01, 2024
District 2 Capital LP
403.00
0.07%
-449.00
-52.70%
Nov 11, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Datum
Art
Verhältnis
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Mar 16, 2023
Merger
4→1
Mar 16, 2023
Merger
4→1
Mehr Anzeigen
